Meng Du

Meng Du

Auto-generated profile, based on publicly available information

Meng Du

Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China; Hubei Clinical Research Center of Metabolic and Cardiovascular Disease, Huazhong University of Science and Technology, Wuhan, China; Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FZFengxiao Zhang
Fengxiao Zhang
YWYan Wang
Yan Wang
LWLin Wang
Lin Wang
XLXi Luo
Xi Luo
KHKun Huang
Kun Huang
KHKai Huang
Kai Huang
Activation of nuclear receptor estrogen receptor α (ERα) exerts cardiovascular protective effects by modulating the expression of ERα target genes. However, the underlying mechanism remains unclear. PARP1 is a ubiquitous multifunctional nuclear enzyme. In this study, we examined the interplay between PARP1 and ERα, and identified PARP1 as an important regulator of ERα-dependent transcription. We showed that PARP1 could directly bind to ERα, and ERα could be poly(ADP-ribosyl)ated by PARP1. Poly(ADP-ribosyl)ation increased ERα binding to estrogen response element (ERE) present in the promoter of target genes and promoted ERα-mediated gene transcription. Estradiol, the ligand of ERα, increased PARP enzymatic activity and enhanced poly(ADP-ribosyl)ation of ERα. Upon treatment with estradiol, ERα binding to ERE- and ERα-dependent gene expression was dramatically increased in cultured vascular smooth muscle cells (VSMCs). Inhibition of PARP1 by PARP inhibitor or PARP1 siRNA decreased ERα binding to ERE and prevented ERα-dependent gene transcription in VSMCs. Further studies revealed that PARP1 served as an indispensible component for the formation of the ERα-ERE complex by directly interacting with ERα. Thus, our results identify PARP1 as a key regulator of ERα in controlling ERα transactivation.

24 February 2022 in iScience
Verified
Journal Article
Open access
MDMeng Du
Meng Du
CWCheng Wang
Cheng Wang
LYLiuye Yang
Liuye Yang
BLBing Liu
Bing Liu
ZZZhe Zheng
Zhe Zheng
KHKai Huang
Kai Huang
The major clinical consequences of atherosclerosis such as myocardial infarction or stroke are because of thrombotic events associated with acute rupture or erosion of an unstable plaque. Here, we identify an lncRNA Noncoding Repressor of NFAT (Nron) as a critical regulator of atherosclerotic plaque stability. Nron overexpression (OE) in vascular smooth muscle cells (VSMC) induces a highly characteristic architecture of more-vulnerable plaques, while Nron knockdown (KD) suppresses the development of atherosclerosis and favors plaque stability. Mechanistically, Nron specifically binds to and negatively regulates NFATc3, thus inhibiting the proliferation and promoting the apoptosis of VSMCs. Moreover, we also provide evidence that Nron increases the production and secretion of VEGFA from VSMCs, which functions as a paracrine factor to enhance intra-plaque angiogenesis. All of these effects contribute to plaque instability. Genetic or pharmacological inhibition of Nron may have potential for future therapy of atherosclerosis.

22 September 2021 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
MDMeng Du
Meng Du
LYLiu Yang
Liu Yang
BLBing Liu
Bing Liu
LYLiuye Yang
Liuye Yang
XMXiaoxiang Mao
Xiaoxiang Mao
KHKai Huang
Kai Huang

20 February 2019 in British Journal of Nutrition
Verified
Journal Article
Open access
SZShuo Zhang
Shuo Zhang
FZFengxiao Zhang
Fengxiao Zhang
MDMeng Du
Meng Du
KHKun Huang
Kun Huang
CWCheng Wang
Cheng Wang
Fe therapy can be effective in heart failure patients both with and without anaemia. However, the role of Fe therapy in such patients is still uncertain. In this review, the aim was to evaluate the efficacy and safety of Fe therapy in adult patients with heart failure who have reduced ejection fraction (HFrEF). Multiple databases (PubMed, Medline, EMBASE, the Cochrane Library and Clinical Trials) were searched up to December 2017 and the reference lists of relevant articles obtained from the search were reviewed. Data extracted from randomised control trials (RCT) selected for the review were pooled using a fixed effects model or a random effects model, according to heterogeneity between trials. Nine RCT were included in this meta-analysis which included a total of 789 patients who received Fe therapy and who in turn were compared with 585 controls. There was significant improvement in the 6-min walk test (19·05 m, 95 % CI 10·48, 27·62) and peak VO2/kg (0·93 ml/kg per min, 95 % CI 0·16, 1·69) in the Fe supplementation arm. With Fe therapy, fewer patients were hospitalised for heart failure (OR: 0·42, 95 % CI 0·27, 0·65), but no relationship was found for total re-hospitalisation (OR: 0·70, 95 % CI 0·32, 1·51) or mortality (OR: 0·70, 95 % CI 0·38, 1·28). Fe therapy has the potential to improve exercise tolerance, reduce re-hospitalisations for patients with HFrEF having Fe deficiency. In addition, Fe supplementation was found to be safe, with no increased rate of adverse events.

10 February 2025 in Advanced Science
Verified
Journal Article
Open access
HQHaojie Qin
Haojie Qin
YZYi Zhong
Yi Zhong
JHJinhui Huang
Jinhui Huang
YMYanli Miao
Yanli Miao
MDMeng Du
Meng Du
KHKai Huang
Kai Huang
In mammals, the activation of thermogenic adipocytes, such as beige and brown adipocytes, can significantly increase overall energy expenditure, offering a promising strategy to combat metabolic diseases. Despite its considerable potential, the regulatory mechanisms governing this activation remain largely elusive. This study bridges this gap by elucidating that tripartite motif 56 (TRIM56), an E3 ubiquitin ligase, is upregulated in response to cold stimuli, thereby promoting the recruitment of beige adipocytes. Notably, the overexpression of TRIM56 in adipocytes is shown to help mice maintain a core temperature under cold conditions, as well as confer protection against diet‐induced obesity. Mechanistically, TRIM56 facilitates the degradation of the transducin‐like enhancer protein 3 (TLE3) protein by promoting its K48‐linked ubiquitination, which subsequently triggers the activation of thermogenic genes in subcutaneousl white adipose tissue and improved the metabolic profiles. These findings unveil a novel function for TRIM56 in adipocyte browning, suggesting its potential as a therapeutic target for the treatment of metabolic disorders.

22 August 2025 in Journal of Advanced Research
Verified
Journal Article
Open access
LYLiuye Yang
Liuye Yang
PWPengchao Wang
Pengchao Wang
KLKaiyuan Liu
Kaiyuan Liu
BLBing Liu
Bing Liu
JZJingbo Zhu
Jingbo Zhu
MDMeng Du
Meng Du
Non-resolving macrophage-mediated inflammation is closely linked to the pathogenesis of systemic inflammatory response syndrome. Despite years of clinical trials attempting to mitigate the harmful effects of excessive inflammation, these efforts have largely been unsuccessful. Therefore, it is essential to develop novel therapeutic strategies. To explore the role of Nron in inflammatory diseases and evaluate the therapeutic effect. Conditional knockout/knockin mice were used for a systematic evaluation of Nron function in lipopolysaccharide (LPS) or cecal ligation and puncture (CLP)-induced sepsis. Quantitative real-time PCR, western blot, luciferase reporter assay, and RNA-RNA interaction assay were performed to investigate mechanisms and identify functional motifs. An enhanced lipid nanoparticle (LNP) formulation was constructed for targeted macrophage delivery and therapy. Moreover, monocytes were obtained from blood of patients with sepsis for in vitro culture, and the serum for enzyme-linked immunosorbent assay (ELISA) detection. Data analysis was conducted using GraphPad Prism 8. Conditional knockout of Nron in myeloid cells exacerbates LPS or CLP-induced sepsis, while the conditional transgenic mice exhibited a survival advantage with alleviated tissue inflammation and damage. Nron enhances sirtuin 1 (SIRT1) deacetylase activity via sponging miR-146a-3p/miR-16-1-3p in macrophages, thus regulating on nuclear factor kappa B (NF-κB) signaling by inhibiting p65 acetylation/phosphorylation directly or via HIF-1 signaling. The conserved functional motif of Nron (NCM2) has a longer half-life and LNP-NCM2 targeted to macrophages effectively alleviated sepsis in mice. Nron serves as a crucial negative regulator of excessive inflammatory responses, and its functional motifs can be used as a potential therapeutic agent for inflammatory diseases such as sepsis.